CN85101722A - 制备二氢哒嗪酮衍生物的方法 - Google Patents

制备二氢哒嗪酮衍生物的方法 Download PDF

Info

Publication number
CN85101722A
CN85101722A CN198585101722A CN85101722A CN85101722A CN 85101722 A CN85101722 A CN 85101722A CN 198585101722 A CN198585101722 A CN 198585101722A CN 85101722 A CN85101722 A CN 85101722A CN 85101722 A CN85101722 A CN 85101722A
Authority
CN
China
Prior art keywords
compound
methyl
structural formula
dihydro
pyridazinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN198585101722A
Other languages
English (en)
Chinese (zh)
Inventor
斯莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of CN85101722A publication Critical patent/CN85101722A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
CN198585101722A 1984-01-13 1985-04-01 制备二氢哒嗪酮衍生物的方法 Pending CN85101722A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (1)

Publication Number Publication Date
CN85101722A true CN85101722A (zh) 1987-01-31

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN198585101722A Pending CN85101722A (zh) 1984-01-13 1985-04-01 制备二氢哒嗪酮衍生物的方法

Country Status (31)

Country Link
US (1) US4654342A (https=)
EP (1) EP0150937B1 (https=)
JP (3) JPS60158181A (https=)
KR (1) KR920006781B1 (https=)
CN (1) CN85101722A (https=)
AT (1) ATE37179T1 (https=)
AU (1) AU572252B2 (https=)
CA (2) CA1251209A (https=)
CS (1) CS248731B2 (https=)
DD (1) DD231350A5 (https=)
DE (1) DE3564941D1 (https=)
DK (1) DK162519C (https=)
ES (3) ES8607949A1 (https=)
FI (1) FI850140L (https=)
GB (1) GB8400863D0 (https=)
GR (1) GR850068B (https=)
HU (1) HU193591B (https=)
IE (1) IE57969B1 (https=)
IL (1) IL74031A (https=)
JO (1) JO1351B1 (https=)
MY (1) MY100124A (https=)
NO (1) NO850129L (https=)
NZ (1) NZ210816A (https=)
PH (1) PH22136A (https=)
PL (1) PL147123B1 (https=)
PT (1) PT79819B (https=)
RO (1) RO92607A (https=)
SU (1) SU1396963A3 (https=)
WO (1) WO1985003076A1 (https=)
ZA (1) ZA85251B (https=)
ZW (1) ZW385A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
WO2019149259A1 (zh) * 2018-02-05 2019-08-08 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung
PL369738A1 (en) * 2001-11-05 2005-05-02 Merck Patent Gmbh Hydrazono-malonitriles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
AU2006310997B2 (en) * 2005-11-14 2013-01-10 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2370070B9 (en) 2008-11-25 2014-04-23 Boehringer Ingelheim Vetmedica GmbH Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
ES2883448T3 (es) 2013-12-04 2021-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
ATE13294T1 (de) * 1981-03-04 1985-06-15 Ciba Geigy Ag Pyridazinone, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und deren verwendung.
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
WO2019149259A1 (zh) * 2018-02-05 2019-08-08 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
CN110117257A (zh) * 2018-02-05 2019-08-13 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途

Also Published As

Publication number Publication date
PT79819A (en) 1985-02-01
CA1251209A (en) 1989-03-14
ES8703846A1 (es) 1987-03-01
EP0150937B1 (en) 1988-09-14
FI850140A7 (fi) 1985-07-14
CA1260471A (en) 1989-09-26
DK9185A (da) 1985-07-14
IL74031A (en) 1988-07-31
ES8607949A1 (es) 1986-06-01
PL147123B1 (en) 1989-04-29
ES8706645A1 (es) 1987-07-01
EP0150937A2 (en) 1985-08-07
PT79819B (en) 1987-01-07
ATE37179T1 (de) 1988-09-15
CS248731B2 (en) 1987-02-12
ES554965A0 (es) 1987-07-01
CA1260471C (https=) 1989-09-26
AU572252B2 (en) 1988-05-05
DE3564941D1 (en) 1988-10-20
JPS63313775A (ja) 1988-12-21
PL251516A1 (en) 1985-12-17
ZW385A1 (en) 1985-08-07
NO850129L (no) 1985-07-15
AU3761185A (en) 1985-07-18
US4654342A (en) 1987-03-31
FI850140L (fi) 1985-07-14
KR850005417A (ko) 1985-08-26
JPS63313776A (ja) 1988-12-21
GR850068B (https=) 1985-05-03
ES549629A0 (es) 1987-03-01
HUT37128A (en) 1985-11-28
HU193591B (en) 1987-11-30
SU1396963A3 (ru) 1988-05-15
ZA85251B (en) 1986-08-27
DK162519B (da) 1991-11-11
IE57969B1 (en) 1993-06-02
GB8400863D0 (en) 1984-02-15
RO92607A (ro) 1987-11-30
KR920006781B1 (ko) 1992-08-17
JPS60158181A (ja) 1985-08-19
EP0150937A3 (en) 1985-08-21
IL74031A0 (en) 1985-04-30
DK162519C (da) 1992-03-30
FI850140A0 (fi) 1985-01-11
ES539446A0 (es) 1986-06-01
PH22136A (en) 1988-06-01
WO1985003076A1 (en) 1985-07-18
MY100124A (en) 1989-12-18
DD231350A5 (de) 1985-12-24
NZ210816A (en) 1987-06-30
IE850069L (en) 1985-07-13
JO1351B1 (en) 1986-11-30
DK9185D0 (da) 1985-01-08

Similar Documents

Publication Publication Date Title
CN85101722A (zh) 制备二氢哒嗪酮衍生物的方法
SA96170263B1 (ar) مشتقات بيريميدين ثنائي أون pyrimidinedione, ثلاثي آزين ثنائي أون triazinedione على أنها مضادات مستقبل ألفا-1-الأدرينالي
CA2471265C (en) Pyrimidotriazines as phosphatase inhibitors
CN1305465A (zh) 芳基链烷酰基哒嗪化合物
US4581356A (en) Triazine derivatives, and pharmaceutical compositions comprising the same
EP0208518B1 (en) 6-phenyl-pyridazinyl compounds
HU197749B (en) Process for producing /3,4-d/pyrimidine derivatives and pharmaceutical compositions comprising these compounds as active ingredient
JP3083544B2 (ja) 心疾患を予防または治療する薬剤
CN1649843A (zh) 新查耳酮衍生物及其应用
US4766123A (en) Methylamidine compounds
US4766122A (en) Cyanoamidine compounds and derivatives thereof
JPH0723375B2 (ja) エルゴリンエステル、その製造方法およびそれを含有する医薬組成物
CA2018485A1 (fr) Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
CN88103114A (zh) 杂环化合物
CN85101925A (zh) 制备杂环化合物及其制药容许盐的方法
CN86108027A (zh) 制备新的2，2′-联-1h-咪唑类的方法
US4632924A (en) 5-(4-substituted)phenyl-2-pyrazinones
EP0340030A2 (en) Triazine derivatives
CN1177960A (zh) 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
CN86105663A (zh) 化合物
CZ20014186A3 (cs) Soli cis-[4-kyan-4-(3-cyklopentyloxy-4-methoxyfenyl)cyklohexan-1-karboxylátu]
CN1107844A (zh) 二氢化茚衍生物和其制法及合成该衍生物的中间体
CN88103112A (zh) 酰胺类化合物
GB1579678A (en) Pyrrolo (3,2-f)-quinazoline-1,3-diamine and compounds
EP0343866A1 (en) Aminophenol derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication